| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
|
|
|
|
|
| |
|
Year
Ended October 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Net income (loss): |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(3,879 |
) |
|
$ |
(5,776 |
) |
| Cancer Vaccines |
|
|
(5,111 |
) |
|
|
(4,889 |
) |
| Anti-Viral Therapeutics |
|
|
(945 |
) |
|
|
(3,075 |
) |
| Other |
|
|
5 |
|
|
|
(31 |
) |
| Total |
|
$ |
(9,930 |
) |
|
$ |
(13,771 |
) |
| |
|
|
|
|
|
|
|
|
| Net
income (loss) |
|
$ |
(9,930 |
) |
|
$ |
(13,771 |
) |
| Total operating costs and expenses |
|
$ |
11,221 |
|
|
$ |
13,875 |
|
| Less non-cash share-based
compensation |
|
|
(4,735 |
) |
|
|
(6,655 |
) |
| Operating
costs and expenses excluding non-cash share-based compensation |
|
$ |
6,486 |
|
|
$ |
7,220 |
|
| |
|
|
|
|
|
|
|
|
| Operating costs and expenses excluding non-cash
share based compensation: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
2,467 |
|
|
$ |
3,206 |
|
| Cancer Vaccines |
|
|
3,265 |
|
|
|
2,355 |
|
| Anti-Viral Therapeutics |
|
|
553 |
|
|
|
1,634 |
|
| Other |
|
|
201 |
|
|
|
25 |
|
| Total |
|
$ |
6,486 |
|
|
$ |
7,220 |
|
| Operating
costs and expenses excluding non-cash share based compensation |
|
$ |
6,486 |
|
|
$ |
7,220 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
October
31, |
|
| |
|
|
2023 |
|
|
|
2022 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
7,523 |
|
|
$ |
16,921 |
|
| Cancer Vaccines |
|
|
17,215 |
|
|
|
9,442 |
|
| Anti-Viral Therapeutics |
|
|
700 |
|
|
|
3,811 |
|
| Other |
|
|
84 |
|
|
|
238 |
|
| Total |
|
$ |
25,522 |
|
|
$ |
30,412 |
|
| Total assets |
|
$ |
25,522 |
|
|
$ |
30,412 |
|
|